Mammoth Biosciences

mammoth.bio

Mammoth Biosciences
Mammoth Biosciences is harnessing the diversity of nature to power the next-generation of CRISPR products. Through the discovery and development of novel CRISPR systems

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

RELAY THERAPEUTICS ANNOUNCES FORMATION OF ONCOLOGY ADVISORY BOARD

BioSpace | March 04, 2020

news image

Relay Therapeutics, a new breed of company at the intersection of computation and biotechnology, announced today the appointment of top oncology experts, scientists and leaders to its newly formed oncology advisory board. “We are at a pivotal moment in the company’s growth and development as we become a clinical-stage company and we are delighted to have such an esteemed group of leaders to advise and support our team,” said Don Bergstrom, M.D., Ph.D., executive vice pre...

Read More

Industry Outlook

BIOMEDICAN ENTERS THE ASTAXANTHIN MARKET THROUGH BIOSYNTHESIS PLATFORM TO TARGET HIGH-VALUE COMPOUND AND DISRUPT THE CURRENT TECHNOLOGIES

BIOMEDICAN | December 03, 2020

news image

BIOMEDICAN, a biotech organization planning patented minimal methods for developing high-value compounds at scale with proprietary yeasts, has entered the Astaxanthin market to diversify products outside of Cannabinoids. This new advancement permits BIOMEDICAN's biosynthesis platform to focus on any high-value compound and fundamentally disturb the current advances. Astaxanthin is a widely used, high-value compound known as a powerful antioxidant and anti-inflammatory. The Ast...

Read More

UNUM THERAPEUTICS ANNOUNCED THE TRANSFER OF BOXR CELL-BASED THERAPY TECHNOLOGY TO SOTIO

Cision PR Newswire | August 31, 2020

news image

Unum Therapeutics Inc. (Nasdaq: UMRX), a biopharmaceutical company focused on developing novel, best-in-class precision kinase inhibitors for a range of patients living with cancer and other unmet medical needs, announced today the sale of its cell-based BOXR programs to SOTIO, a clinical stage immuno-oncology company owned by PPF Group. Under the terms of the agreement, SOTIO will make an upfront payment of $8.1 million for the BOXR technology and will assume development of Unum's lead cand...

Read More

Medical

AMBAGON THERAPEUTICS LAUNCHES WITH $85 MILLION SERIES A TO ADVANCE PIONEERING MOLECULAR GLUE PLATFORM AND PROGRESS PIPELINE

Ambagon Therapeutics | January 07, 2022

news image

Ambagon Therapeutics, a biotechnology company unlocking intrinsically disordered proteins and other difficult-to-target protein classes, announced an $85 million Series A to augment its drug discovery platform and to advance its pipeline of molecular glues. The financing was led by Nextech Invest. Ambagon was previously seeded by RA Capital Management, Droia Ventures, Inkef Capital, AbbVie Ventures, MRL Ventures Fund, and Mission BioCapital. Investors from the seed round joined th...

Read More
news image

RELAY THERAPEUTICS ANNOUNCES FORMATION OF ONCOLOGY ADVISORY BOARD

BioSpace | March 04, 2020

Relay Therapeutics, a new breed of company at the intersection of computation and biotechnology, announced today the appointment of top oncology experts, scientists and leaders to its newly formed oncology advisory board. “We are at a pivotal moment in the company’s growth and development as we become a clinical-stage company and we are delighted to have such an esteemed group of leaders to advise and support our team,” said Don Bergstrom, M.D., Ph.D., executive vice pre...

Read More
news image

Industry Outlook

BIOMEDICAN ENTERS THE ASTAXANTHIN MARKET THROUGH BIOSYNTHESIS PLATFORM TO TARGET HIGH-VALUE COMPOUND AND DISRUPT THE CURRENT TECHNOLOGIES

BIOMEDICAN | December 03, 2020

BIOMEDICAN, a biotech organization planning patented minimal methods for developing high-value compounds at scale with proprietary yeasts, has entered the Astaxanthin market to diversify products outside of Cannabinoids. This new advancement permits BIOMEDICAN's biosynthesis platform to focus on any high-value compound and fundamentally disturb the current advances. Astaxanthin is a widely used, high-value compound known as a powerful antioxidant and anti-inflammatory. The Ast...

Read More
news image

UNUM THERAPEUTICS ANNOUNCED THE TRANSFER OF BOXR CELL-BASED THERAPY TECHNOLOGY TO SOTIO

Cision PR Newswire | August 31, 2020

Unum Therapeutics Inc. (Nasdaq: UMRX), a biopharmaceutical company focused on developing novel, best-in-class precision kinase inhibitors for a range of patients living with cancer and other unmet medical needs, announced today the sale of its cell-based BOXR programs to SOTIO, a clinical stage immuno-oncology company owned by PPF Group. Under the terms of the agreement, SOTIO will make an upfront payment of $8.1 million for the BOXR technology and will assume development of Unum's lead cand...

Read More
news image

Medical

AMBAGON THERAPEUTICS LAUNCHES WITH $85 MILLION SERIES A TO ADVANCE PIONEERING MOLECULAR GLUE PLATFORM AND PROGRESS PIPELINE

Ambagon Therapeutics | January 07, 2022

Ambagon Therapeutics, a biotechnology company unlocking intrinsically disordered proteins and other difficult-to-target protein classes, announced an $85 million Series A to augment its drug discovery platform and to advance its pipeline of molecular glues. The financing was led by Nextech Invest. Ambagon was previously seeded by RA Capital Management, Droia Ventures, Inkef Capital, AbbVie Ventures, MRL Ventures Fund, and Mission BioCapital. Investors from the seed round joined th...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us